Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01288-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ariane Amoura und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM, IAME, Paris, France. Hauptthemen laut MEDLINE: Azabicyclo Compounds, beta-Lactamases, Escherichia coli, Aztreonam. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The combination of aztreonam (ATM) and avibactam (AVI) is an attractive option to treat infections caused by extended spectrum β-lactamase plus NDM-1-producing Enterobacteriaceae . Since ATM activity was shown to be severely impacted by an increase in the inoculum size in vitro , we wondered whether ATM-AVI activity could be impaired in high-inoculum infections. We analyzed the impact of the inoculum size on ATM-AVI activity in vitro and in a murine model of peritonitis due to susceptible Escherichia coli CFT073-pTOPO and its isogenic derivatives producing NDM-1 ( E. coli CFT073-NDM1) and CTX-M-15 plus NDM-1 ( E. coli CFT073-CTXM15-NDM1). The impact of the inoculum size on bacterial morphology was studied by microscopic examination. In vitro , at standard (10 5 ) inoculum, E. coli CFT073-CTXM15-NDM1 was resistant to ATM but susceptible to the ATM-AVI combination. At high (10 7 ) inoculum, MICs of ATM alone and of the ATM-AVI combination reached >512 and 64 mg/L, respectively, against all tested strains. ATM led to bacterial filamentation when active against the bacteria, i.e., in monotherapy or in combination with AVI against susceptible E. coli CFT073-pTOPO and only in combination with AVI against E. coli CFT073-CTXM15-NDM1. In vivo , increase in the inoculum led to a drastic decrease in the activity of ATM alone against E. coli CFT073-pTOPO and ATM-AVI against E. coli CFT073-CTXM15-NDM1. Our results suggest a high in vivo impact of the inoculum increase on the activity of ATM alone against ATM-susceptible E. coli and of ATM-AVI against CTX-M-15 plus NDM-1 producing E. coli . Clinicians must be aware of the risk of failures when using ATM-AVI in high-inoculum infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, INSERM, IAME, Paris, France.
- Universite Sorbonne Paris Nord, INSERM, IAME, Bobigny, France.
- Laboratoire de Pharmacologie, Hôpital Jean Verdier, Bondy, France.
- Service de Médecine Interne, Hôpital Beaujon, Clichy, France.
- Laboratoire de toxicologie, Hôpital Bichat, Paris, France.
ORCID-Profile: Agnès Lefort
Zitieren
APA
Amoura, A., Benchetrit, L., Magréault, S., Chosidow, S., Le Menestrel, A., Jullien, V., de Lastours, V., Chau, F., Dion, S., Massias, L., Fantin, B., & Lefort, A. (2025). Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01288-22
Vancouver
Amoura A, Benchetrit L, Magréault S, Chosidow S, Le Menestrel A, Jullien V, et al. Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01288-22
BibTeX
@article{Amoura2025,
author = {Amoura, Ariane and Benchetrit, Laura and Magréault, Sophie and Chosidow, Samuel and Le Menestrel, Alice and Jullien, Vincent and de Lastours, Victoire and Chau, Françoise and Dion, Sara and Massias, Laurent and Fantin, Bruno and Lefort, Agnès},
title = {Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01288-22}
}
EUVIMED